Neurocrine Biosciences Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Neurocrine Biosciences de 27.1% y 13.8% por año respectivamente. Se prevé que el BPA crezca en un 25.8% al año. Se espera que la rentabilidad financiera sea de 32.3% en 3 años.

Información clave

27.1%

Tasa de crecimiento de los beneficios

25.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.7%
Tasa de crecimiento de los ingresos	13.8%
Rentabilidad financiera futura	32.3%
Cobertura de analistas	Good
Última actualización	11 Jun 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

May 08

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:NBIX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	2,973	916	954	1,014	20
12/31/2025	2,551	675	762	816	24
12/31/2024	2,219	431	553	617	23
3/31/2024	1,982	370	614	645	N/A
12/31/2023	1,887	250	362	390	N/A
9/30/2023	1,784	191	385	409	N/A
6/30/2023	1,673	176	281	296	N/A
3/31/2023	1,599	64	237	255	N/A
12/31/2022	1,489	155	323	339	N/A
9/30/2022	1,389	58	177	201	N/A
6/30/2022	1,297	12	133	164	N/A
3/31/2022	1,208	71	102	129	N/A
12/31/2021	1,134	90	233	257	N/A
9/30/2021	1,069	445	328	347	N/A
6/30/2021	1,032	365	251	265	N/A
3/31/2021	1,045	402	266	280	N/A
12/31/2020	1,046	407	218	229	N/A
9/30/2020	1,042	93	222	232	N/A
6/30/2020	1,006	205	337	350	N/A
3/31/2020	887	177	283	295	N/A
12/31/2019	788	37	132	147	N/A
9/30/2019	675	21	82	100	N/A
6/30/2019	605	18	44	71	N/A
3/31/2019	519	-39	0	27	N/A
12/31/2018	451	21	77	101	N/A
9/30/2018	414	10	70	91	N/A
6/30/2018	323	-52	2	13	N/A
3/31/2018	233	-106	-63	-55	N/A
12/31/2017	162	-143	N/A	-94	N/A
9/30/2017	67	-194	N/A	-167	N/A
6/30/2017	6	-220	N/A	-188	N/A
3/31/2017	N/A	-200	N/A	-154	N/A
12/31/2016	15	-141	N/A	-106	N/A
9/30/2016	15	-126	N/A	-90	N/A
6/30/2016	15	-123	N/A	-77	N/A
3/31/2016	15	-107	N/A	-49	N/A
12/31/2015	20	-89	N/A	-38	N/A
9/30/2015	20	-79	N/A	-38	N/A
6/30/2015	20	-60	N/A	-32	N/A
3/31/2015	20	-50	N/A	-56	N/A
12/31/2014	N/A	-61	N/A	-47	N/A
9/30/2014	1	-52	N/A	-43	N/A
6/30/2014	1	-47	N/A	-41	N/A
3/31/2014	2	-46	N/A	-41	N/A
12/31/2013	3	-46	N/A	-30	N/A
9/30/2013	24	-26	N/A	-28	N/A
6/30/2013	33	-18	N/A	-25	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (27.1% al año) de NBIX es superior a la tasa de ahorro (2.4%).

Beneficios vs. Mercado: Se prevé que los beneficios (27.1% al año) de NBIX crezcan más rápidamente que el mercado US (14.8% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de NBIX crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (13.8% al año) de NBIX crezcan más rápidamente que los del mercado US (8.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 13.8% al año) de NBIX crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de NBIX sea alta dentro de 3 años (32.3%)

Neurocrine Biosciences Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates fall by 12%

Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024

Neurocrine Biosciences, Inc. Provides Earnings Guidance for the Full Year of 2024

Neurocrine Biosciences, Inc. Provides Sales Guidance for the Year 2023

Consensus EPS estimates increase by 22%

Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2023

Recent updates

Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

Independent Director notifies of intention to sell stock

Neurocrine Biosciences Announces CEO Changes

Neurocrine Biosciences Announces CEO Changes

Neurocrine Biosciences, Inc. Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis

Chief Financial Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc. and Diurnal Ltd. Presents Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024

Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024

Consensus EPS estimates fall by 12%

Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024

Neurocrine Biosciences, Inc. Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules

Insufficient new directors

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data

Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community

Neurocrine Biosciences, Inc. Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

Chief Commercial Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc., Annual General Meeting, May 22, 2024

Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

Independent Director notifies of intention to sell stock

Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

Independent Director notifies of intention to sell stock

New minor risk - Shareholder dilution

Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside

CEO & Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Provides Earnings Guidance for the Full Year of 2024

Insider notifies of intention to sell stock

Neurocrine Biosciences, Inc. to Report Fiscal Year 2023 Results on Feb 07, 2024

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Insider notifies of intention to sell stock

Chief Human Resources Officer notifies of intention to sell stock

Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt

Insider notifies of intention to sell stock

Sosei Heptares’ Partner Neurocrine Biosciences Confirms Its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies

Neurocrine Biosciences, Inc. Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation

Neurocrine Biosciences, Inc. Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation

Neurocrine Biosciences, Inc. Reports Update on the Phase 2 Clinical Trial

Neurocrine Biosciences® Presents Ingrezza® (Valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated with Huntington's Disease Through Week 50 At Huntington Study Group 2023

Neurocrine Biosciences, Inc. Provides Sales Guidance for the Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Neurocrine Biosciences, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts New Drug Application for Ingrezza®? (Valbenazine) Oral Granules Sprinkle Formulation

Independent Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)

Neurocrine Biosciences Inc. Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults

Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Independent Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders Demonstrating Comparable Improvement over Time in Tardive Dyskinesia Severity and Impact Following Treatment with INGREZZA (Valbenazine) Capsules

Neurocrine Biosciences, Inc. Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease

CEO & Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Announces FDA Approval of INGreZZA (valbenazine) Capsules for the Treatment of Chorea Associated with Huntington's Disease

Consensus EPS estimates increase by 22%

Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Neurocrine Biosciences, Inc. Announces Retirement of Eiry W. Roberts as Chief Medical Officer

Neurocrine Biosciences, Inc. to Report Q2, 2023 Results on Aug 01, 2023

We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease

Neurocrine Biosciences, Inc. Presents INGreZZA(R) (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress Elevate

Neurocrine Biosciences, Inc. Announces Publication of Full KINECT(TM)-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in the Lancet Neurology

Neurocrine Biosciences, Inc. Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023

Consensus EPS estimates fall by 23%

Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Human Resources Officer notifies of intention to sell stock